American Generics (India) Limited
About American Generics (India) Limited
Data last updated:
American Generics (India) Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 April 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG1995PLC020046. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹26.76 Lakh. It is led by directors including Venkatasubrahmanyan Ramakrishnan (Managing Director) and Sunil Srivastava.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flat No.301 Sri Rama Mountview Road No.2 Banjarahills Hyderabad, Telangana, India.
As per the financials filed for FY 2024, the company reported a revenue of ₹30.24 Lakh, a growth of 33% compared to the previous year. For the same year it recorded a net profit of ₹7.47 Lakh (net margin 24.7%) and EBITDA of ₹8.09 Lakh (EBITDA margin 26.8%). Revenue has declined at a compounded annual rate (CAGR) of 3% over three years and 4% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
CIN History of American Generics (India) Limited
American Generics (India) has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239TG1995PLC020046, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TG1995PLC020046 | Current |
| U24239AP1995PTC020046 | Previous |
| U24239AP1995PLC020046 | Previous |
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressFlat No.301 Sri Rama Mountview Road No.2 Banjarahills Hyderabad, Telangana, India
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of American Generics (India) Limited
The main business activity of American Generics (India) is professional, scientific and technical. In detail, this covers management consultancy activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M3 | Management consultancy activities | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of American Generics (India) Limited FY 2025 filings available
American Generics (India) Limited reported revenue of ₹30.24 Lakh (up 33% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of American Generics (India) Limited
Revenue rose 33% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 4%. EBITDA rose 808% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of American Generics (India) Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹8.09 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹7.47 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of American Generics (India) Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 26.8% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 24.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of American Generics (India) are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of American Generics (India) Limited
American Generics (India) has 4 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sunil Srivastava | Director | 19 Apr 1995 | 31 Years 6 Months | Current |
| Venkatasubrahmanyan Ramakrishnan | Managing Director | 19 Apr 1995 | 31 Years 6 Months | Current |
| Bhupendera Prashanth Ramakrishnan | Director | 28 May 2018 | 8 Years 4 Months | Current |
| Lalitha Ramakrishnan | Director | 04 Jul 2001 | 25 Years 3 Months | Current |
Peer Comparison of American Generics (India) Limited
American Generics (India) Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Massy Healthcare Private Limited | ₹30.46 Lakh (FY 2025) | •••• | •••• | -6.0% | •••• | Ambala Cantt, Haryana, India |
| Seora Life Sciences Private Limited | ₹30.46 Lakh (FY 2018) | •••• | •••• | -42.0% | •••• | Thane, Maharashtra, India |
| Waft Pharma Private Limited | ₹30.37 Lakh (FY 2022) | •••• | •••• | 4519.0% | •••• | Rajamahendravaram, Andhra Pradesh, India |
| Reddot Life Private Limited | ₹30.28 Lakh (FY 2024) | •••• | •••• | -86.0% | •••• | Bangalore, Karnataka, India |
| Mumbai Corporate Private Limited | ₹30.26 Lakh (FY 2025) | •••• | •••• | 107.0% | •••• | Mumbai, Maharashtra, India |
| American Generics (India) Limited this company | ₹30.24 Lakh (FY 2024) | •••• | •••• | 33.0% | •••• | Hyderabad, Telangana, India |
| Sava Medica Limited | ₹30.21 Lakh (FY 2024) | •••• | •••• | •••• | Wadhwan, Gujarat, India | |
| Thebes Pharmaceuticals Private Limited | ₹30.2 Lakh (FY 2025) | •••• | •••• | 58.0% | •••• | New Delhi, Delhi, India |
| Sarosh Pharmaceuticals Private Limited | ₹30.04 Lakh (FY 2025) | •••• | •••• | 0.0% | •••• | Bahraich, Uttar Pradesh, India |
| Accufine Pharmaceuticals Private Limited | ₹30 Lakh (FY 2025) | •••• | •••• | •••• | Ahmedabad, Gujarat, India | |
| Floare & Zuvaka Global Pharma Private Limited | ₹29.95 Lakh (FY 2025) | •••• | •••• | 188.0% | •••• | Greater Noida, Uttar Pradesh, India |
Peers are the five companies nearest above and the five nearest below American Generics (India) by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of American Generics (India) Limited
American Generics (India) Limited is audited by C K S ASSOCIATES for the financial year 2018.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| C K S ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of American Generics (India) Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of American Generics (India) Limited
American Generics (India) Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at American Generics (India) Limited
Employment history and EPFO contributions of people linked to American Generics (India).
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on American Generics (India) Limited
American Generics (India) Limited has 5 board changes on record since 1995: 4 appointments and 1 cessation. The latest: Bhupendera Prashanth Ramakrishnan ceased to be Additional Director on 20 Sep 2018.
Credit Ratings, Litigation & Regulatory Alerts for American Generics (India) Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by American Generics (India) Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of American Generics (India) Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of American Generics (India) Limited
American Generics (India) has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of American Generics (India) Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about American Generics (India) Limited
American Generics (India) is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 April 1995 (31+ years old) and is registered under CIN U24239TG1995PLC020046.
American Generics (India) reported revenue of ₹30.24 Lakh for FY 2024 (up 33% YoY).
American Generics (India) has 4 current directors:
- Venkatasubrahmanyan Ramakrishnan - Managing Director
- Sunil Srivastava - Director
- Bhupendera Prashanth Ramakrishnan - Director
- Lalitha Ramakrishnan - Director
American Generics (India) reported a net profit of ₹7.47 Lakh (net margin 24.7%) and EBITDA of ₹8.09 Lakh (EBITDA margin 26.8%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of American Generics (India) is -3% over three years and -4% over five years. In the latest year (FY 2024) revenue rose 33%. CAGR is the steady yearly rate that links the first and the last year.
No. American Generics (India) has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of American Generics (India) is U24239TG1995PLC020046. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
American Generics (India) was incorporated on 19 April 1995, making it 31+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of American Generics (India) by revenue are Massy Healthcare Private Limited, Seora Life Sciences Private Limited, Waft Pharma Private Limited, Reddot Life Private Limited, Mumbai Corporate Private Limited and 5 more, all in the Pharma industry (Formulations).
Bhupendera Prashanth Ramakrishnan ceased to be Additional Director on 20 Sep 2018. Bhupendera Prashanth Ramakrishnan was appointed as Director on 28 May 2018. Lalitha Ramakrishnan was appointed as Director on 04 Jul 2001. American Generics (India) has 5 board changes on record in total.
The registered office of American Generics (India) is at Flat No.301 Sri Rama Mountview Road No.2 Banjarahills Hyderabad, Telangana, India.